Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study
Journal of Neurochemistry · 2023
DOI: 10.1111/jnc.15944 ↗At a glance
Journal article in Journal of Neurochemistry, 2023. Written by Dorota Koníčková and 18 co-authors. Institution: Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic. Major MEDLINE topics: Neurodegenerative Diseases. Cited 18 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: European Regional Development Fund - Project ENOCH, IGA_PrF_2023_031, IGA-LF-2022-014.
Abstract (original language)
Neurodegenerative diseases are a broad heterogeneous group affecting the nervous system. They are characterized, from a pathophysiological perspective, by the selective involvement of a subpopulation of nerve cells with a consequent clinical picture of a disease. Clinical diagnoses of neurodegenerative diseases are quite challenging and often not completely accurate because of their marked heterogeneity and frequently overlapping clinical pictures. Efforts are being made to define sufficiently specific and sensitive markers for individual neurodegenerative diseases or groups of diseases in order to increase the accuracy and speed of clinical diagnosis. Thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (CSF) and serum (α‐synuclein [α‐syn], tau protein [t‐tau], phosphorylated tau protein [p‐tau], β‐amyloid [Aβ], clusterin, chromogranin A [chromogrA], cystatin C [cyst C], neurofilament heavy chains [NFH], phosphorylated form of neurofilament heavy chains [pNF‐H], and ratio of tau protein/amyloid beta [Ind tau/Aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α‐synucleinopathies and four‐repeat (4R‐) tauopathies characterized by tau protein isoforms with four microtubule‐binding domains. In this study, we analyzed a cohort of 229 patients divided into four groups: (1) Parkinson's disease (PD) + dementia with Lewy bodies (DLB) ( n = 82), (2) multiple system atrophy (MSA) ( n = 25), (3) progressive supranuclear palsy (PSP) + corticobasal syndrome (CBS) ( n = 30), and (4) healthy controls (HC) ( n = 92). We also focused on analyzing the biomarkers in relation to each other with the intention of determining whether they are useful in distinguishing among individual proteinopathies. Our results indicate that the proposed set of biomarkers, when evaluated in CSF, is likely to be useful for the differential diagnosis of MSA versus 4RT. However, these biomarkers do not seem to provide any useful diagnostic information when assessed in blood serum. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic.
- Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- Neurology Outpatient Clinic "St. Moritz", Olomouc, Czech Republic.
- Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, Palacky University, Olomouc, Czech Republic.
- Laboratory of Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University, University Hospital Olomouc, Olomouc, Czech Republic.
- Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic.
ORCID profiles: Dorota Koníčková, Kateřina Menšíková, Kateřina Klíčová, Monika Chudáčková, Michaela Kaiserová, Hana Přikrylová, Pavel Otruba, Martin Nevrlý, Petr Hluštík, Eva Hényková, Michal Kaleta, David Friedecký, Radoslav Matěj, Miroslav Strnad, Ondřej Novák, Lucie Plíhalová, Raymond Rosales, Carlo Colosimo, Petr Kaňovský
Funding
- European Regional Development Fund - Project ENOCH
- IGA_PrF_2023_031
- IGA-LF-2022-014
- NV 19-04-00090
Cite
APA
Koníčková, D., Menšíková, K., Klíčová, K., Chudáčková, M., Kaiserová, M., Přikrylová, H., Otruba, P., Nevrlý, M., Hluštík, P., Hényková, E., Kaleta, M., Friedecký, D., Matěj, R., Strnad, M., Novák, O., Plíhalová, L., Rosales, R., Colosimo, C., & Kaňovský, P. (2023). Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15944
Vancouver
Koníčková D, Menšíková K, Klíčová K, Chudáčková M, Kaiserová M, Přikrylová H, et al. Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study. Journal of Neurochemistry. 2023. doi:10.1111/jnc.15944
BibTeX
@article{Konkov2023,
author = {Koníčková, Dorota and Menšíková, Kateřina and Klíčová, Kateřina and Chudáčková, Monika and Kaiserová, Michaela and Přikrylová, Hana and Otruba, Pavel and Nevrlý, Martin and Hluštík, Petr and Hényková, Eva and Kaleta, Michal and Friedecký, David and Matěj, Radoslav and Strnad, Miroslav and Novák, Ondřej and Plíhalová, Lucie and Rosales, Raymond and Colosimo, Carlo and Kaňovský, Petr},
title = {Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies: A prospective, open, cross‐correlation study},
journal = {Journal of Neurochemistry},
year = {2023},
doi = {10.1111/jnc.15944}
}
EUVIMED